ADVERTISEMENT

If you are seeing this message, you may be experiencing temporary network problems. Please wait a few minutes and refresh the page. If the problem persists, you may wish to report it to your local Network Manager.

It is also possible that your web browser is not configured or not able to display style sheets. In this case, although the visual presentation will be degraded, the site should continue to be functional. We recommend using the latest version of Microsoft or Mozilla web browser to help minimise these problems.

Wiley InterScience

Epilepsia

Epilepsia

Volume 24 Issue 3, Pages 368 - 376

Published Online: 5 Nov 2007

© 2010 International League Against Epilepsy



< Previous Abstract  |  Next Abstract >

Save Article to My Profile      Download Citation      Request Permissions

Abstract |  References  |  Full Text: PDF (Size: 553K)  | Related Articles | Citation Tracking

Reduction of Two-Drug Therapy in Intractable Epilepsy
Dieter Schmidt 1
  1 Abteilung für Neurologie, Klinikum Charlottenburg, Freie Universität Berlin, Spandauer Damm 130, 1000 Berlin 19, Federal Republic of Germany.
Copyright 1983 International League Against Epilepsy
KEYWORDS
Reduction of drug therapy • Discontinuation of drug therapy • Intractable epilepsy • Antiepileptic drug withdrawal

Summary: The effects of reducing two-drug treatment to single-drug therapy were studied prospectively in 36 patients with intractable complex partial seizures. In 30 patients (83%) this was possible without an increase in seizure frequency. In six patients (17%) the number of seizures was higher during single-drug therapy. The slow transfer was not complicated by unwanted withdrawal effects. The plasma concentration of the single drug was raised if necessary until clinical drug toxicity was observed. An improvement in seizure control was surprisingly noted in 13 patients (36%). In two patients seizures were completely controlled. In one patient a seizure reduction of 87% was observed. The number of patients with clinical side effects was similar during two-drug and single-drug therapy. The number of side effects was lower during single-drug therapy. Reduction of polypharmacy may be beneficial for patients with intractable epilepsy.

RESUMEN

Los efectos de la reducción de un régimen de dos drogas a una sóla droga han sido estudiados prospec-tivamente en 36 enfermos con ataques parciales com-plejos resistentes al tratamiento. En 30 casos (83%) este cambio fué posible sin que aumentase la fre-cuencia de los ataques. En 6 pacientes (17%) el número de ataques fué más elevado durante el tratamiento con una sóla medicación. El cambio realizado lentamente no se acompañó de efectos contraprodu-centes. La concentración plasmática de la droga única fué incrementada cuando se estimó necesario, hasta que se observo toxicidad clinica. Sorprendentemente en 13 enfermos (36%) se observó una mejoria en el control de los ataques. En dos enfermos se consiguio un control total. En un enfermo se observó una reducción de los ataques de un 87%. El nümero de enfermos con intolerancia clínica fué semejante durante las fases de dos drogas y de droga única. La reducción de la polifarmacia puede ser beneficiosa en casos de ataques resistentes al tratamiento múltiple.

ZUSAMMENFASSUNG

Die Wirkungen der Reduktion einer 2-Medika-menten Therapie auf Monotherapie wurde prospektiv bei 36 Patienten mit unbeeinflussbaren, komplexen Partialanfällen untersucht. Bei 30 Patienten (83%) war das ohne Erhöhung der Anfallsfrequenz möglich. Bei 6 Patienten (17%) war die Anzahl der Anfälle während der Monotherapie höher. Das langsame Umsetzen war nicht durch ungewiinschte Entzugssymptome kompli-ziert. Die Plasmakonzentration des alleine ver-abfolgten Medikaments wurde–wenn nötig–so lange erhöht, bis klinisch toxische Symptome auftraten. Eine Verbesserung der Anfallskontrolle wurde iiberra-schenderweise bei 13 Patienten registriert (36%)). 2 Patienten wurden anfallsfrei. Ein Patient erlebte eine An-fallsreduktion um 87%. Die Anzahl der Patienten mit-klinischen Nebenwirkungen war unter Monotherapie gleich wie unter 2-Medikamentenstherapie. Die Anzahl der Nebenwirkungen jedoch war unter Monotherapie niedriger. Eine Reduktion der Polypharmazie kann sich vorteilhaft für Patienten mit therapieresis-tenter Epilepsie auswirken.


Received June 30, 1982; revision received December 28, 1982.

DIGITAL OBJECT IDENTIFIER (DOI)
10.1111/j.1528-1157.1983.tb04900.x About DOI

Related Articles

  • Find other articles like this in Wiley InterScience
  • Find articles in Wiley InterScience written by any of the authors

Wiley InterScience is a member of CrossRef.

Cross Ref Member

Latest News & Information
EPI Impact Factor

Sign Up Now
Sign Up Now
Sign-up for Content Alerts
Latest News & Information

Sign up for the Neurology NewsWire.

Neuro Newsletter

Get 6 free issues of breaking news and research delivered to your inbox each year!

Sign Up Now
Wiley Medical Twitter